Targeted Mesoporous Silica Nanocarriers in Oncology
- PMID: 27262488
- DOI: 10.2174/1389450117666160603023037
Targeted Mesoporous Silica Nanocarriers in Oncology
Abstract
Background: Cancer is one of the major leading causes of death worldwide and its prevalence will be higher in the coming years due to the progressive aging of the population. The development of nanocarriers in oncology has provided a new hope in the fight against this terrible disease.
Objective: Among the different types of nanoparticles which have been reported in the scientific literature, mesoporous silica nanoparticles (MSNs) are very promising materials due to their inherent properties such as high loading capacity of many different drugs, excellent biocompatibility and easy functionalization.
Results: This review presents the current state of the art related to the development of mesoporous silica nanocarriers for antitumoral therapy paying special attention on targeted MSN able to selectively destroy tumoral cells, reducing the side damage in healthy ones, and the basic principles of targeting tumoral tissues and cells.
Conclusions: MSNs constitute a promising nanomaterial for drug delivery applications in antitumoral therapy as a consequence of its unique properties such as excellent biocompatibility, high loading capacity, robustness, easy production and existence of multiple strategies for their functionalization with a myriad of bio-organic moieties. In the coming years, the clever application of this material would provide novel alternatives for the treatment of this complex disease.
Keywords: Nanomedicine; cancer; mesoporous silica nanoparticles; nanooncology; nanoparticles; targeted nanocarriers.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
Similar articles
-
Advances in Functionalized Mesoporous Silica Nanoparticles for Tumor Targeted Drug Delivery and Theranostics.Curr Pharm Des. 2017;23(23):3367-3382. doi: 10.2174/1381612822666161025153619. Curr Pharm Des. 2017. PMID: 27784244 Review.
-
Smart Mesoporous Silica Nanocarriers for Antitumoral Therapy.Curr Top Med Chem. 2015;15(22):2306-15. doi: 10.2174/1568026615666150605114826. Curr Top Med Chem. 2015. PMID: 26043739 Review.
-
Advances in the Use of Multifunctional Mesoporous Silica Nanoparticles and Related Nanomaterials as Carriers for the Cancer Treatment.Curr Drug Metab. 2018;19(2):131-141. doi: 10.2174/1389200218666170728120440. Curr Drug Metab. 2018. PMID: 28758578 Review.
-
Tailored Mesoporous Silica Nanoparticles for Controlled Drug Delivery: Platform Fabrication, Targeted Delivery, and Computational Design and Analysis.Mini Rev Med Chem. 2018;18(11):976-989. doi: 10.2174/1389557516666160505114814. Mini Rev Med Chem. 2018. PMID: 27145854 Review.
-
Mesoporous silica nanoparticles in nanomedicine applications.J Mater Sci Mater Med. 2018 May 8;29(5):65. doi: 10.1007/s10856-018-6069-x. J Mater Sci Mater Med. 2018. PMID: 29737405 Review.
Cited by
-
Functional Mesoporous Silica Nanocomposites: Biomedical applications and Biosafety.Int J Mol Sci. 2019 Feb 20;20(4):929. doi: 10.3390/ijms20040929. Int J Mol Sci. 2019. PMID: 30791663 Free PMC article. Review.
-
Antioxidant Nanomaterial Based on Core⁻Shell Silica Nanospheres with Surface-Bound Caffeic Acid: A Promising Vehicle for Oxidation-Sensitive Drugs.Nanomaterials (Basel). 2019 Feb 6;9(2):214. doi: 10.3390/nano9020214. Nanomaterials (Basel). 2019. PMID: 30736331 Free PMC article.
-
Targeted and redox-responsive drug delivery systems based on carbonic anhydrase IX-decorated mesoporous silica nanoparticles for cancer therapy.Sci Rep. 2020 Sep 2;10(1):14447. doi: 10.1038/s41598-020-71071-1. Sci Rep. 2020. PMID: 32879359 Free PMC article.
-
Cancer cell targeting and therapeutic delivery of silver nanoparticles by mesoporous silica nanocarriers: insights into the action mechanisms using quantitative proteomics.Nanoscale. 2019 Mar 7;11(10):4531-4545. doi: 10.1039/c8nr07667g. Nanoscale. 2019. PMID: 30806414 Free PMC article.
-
Mesoporous Silica Nanoparticles Loaded with Resveratrol Are Used for Targeted Breast Cancer Therapy.J Oncol. 2022 Sep 19;2022:8471331. doi: 10.1155/2022/8471331. eCollection 2022. J Oncol. 2022. PMID: 36245986 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous